Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| P30CA046934 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Low accrual
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Cancer Institute (NCI) | NIH |
Not provided
Not provided
Not provided
Not provided
This is a single arm phase II study of brigatinib alone for patients with brain metastases from anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC), who have either not been treated previously with a tyrosine kinase inhibitor (TKI) targeting ALK or who have had prior exposure to crizotinib.
In this single-arm phase II trial, patients with brain metastases from ALK+ NSCLC will be treated with brigatinib alone without upfront brain irradiation. Patients will have close monitoring with clinical follow up visits and brain magnetic resonance imaging (MRI) surveillance, which will maximize safety and allow for early treatment if disease progression is observed. If brigatinib alone can demonstrate high rates of CNS disease control, these data could support a strategy of upfront brigatinib alone for carefully selected patients with brain metastases from ALK+ NSCLC.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients with ALK+ NSCLC and brain metastases | Experimental | Including patients with brain metastases from ALK (anaplastic lymphoma kinase) positive NSCLC (non-small cell lung cancer), who are either neurologically asymptomatic or who have only mild neurologic symptoms (RTOG [Radiation therapy Oncology Group] acute neurologic morbidity score 0-2) from their brain metastases, who are TKI (tyrosine kinase inhibitor) naïve or who have had prior exposure to crizotinib, but who are naïve to brigatinib and other ALK TKIs including alectinib, lorlatinib, and ceritinib. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Brigatinib | Drug | At day 1, all patients will be started on brigatinib 90 mg daily for 7 days, before escalating to 180 mg daily thereafter as tolerated. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants Who Meet Disease Control Rate (DCR) Criteria of Brain Metastases at 3 Months | DCR is defined as complete response (CR), partial response (PR), or stable disease (SD) as defined by the RANO-BM (Response Assessment in Neuro-Oncology Criteria - Brain Metastases) criteria. | 13-week MRI ±7 days |
| Measure | Description | Time Frame |
|---|---|---|
| Time Until Progression With Brigatinib Alone (Part 1) | Time until any CNS progressive disease (PD) by RANO-BM criteria and rates at follow up intervals | up to 24 months |
| Time Until Progression With Brigatinib Alone (Part 2) |
| Measure | Description | Time Frame |
|---|---|---|
| Analysis of Blood at Baseline and at Progression to Correlate With Clinical Outcomes | Evaluation of cfDNA at baseline and progression to correlate with clinical outcomes, including incidence of disease recurrence per RANO-BM and RECIST 1.1, survival status by percentage of patients alive at 2 years, and patient rating of quality of life per EORTC QLQ-BN20 and EORTC QLQ-C30 questionnaires. | up to 24 months |
Inclusion Criteria:
Provision to sign and date the consent form.
Stated willingness to comply with all study procedures and be available for the duration of the study.
Ability to take and retain oral medications.
Age ≥18 years.
Patients with ALK+ lung cancer with evidence of ≥1 previously untreated brain metastases on brain MRI. Prior therapy (radiation or surgery) for brain metastases is allowed. However, patients must have ≥1 previously untreated at the time of enrollment.
Patients may be ALK TKI naïve OR have had prior crizotinib therapy.
Patients may be included if they are asymptomatic from their brain metastases (RTOG/EORTC grade 0) or if they have mild symptoms from their brain metastases not to exceed RTOG/ EORTC grade 1 or 2 (Grade 1: Fully functional status (i.e. able to work) with minor neurological findings, no medication needed; Grade 2: Neurological findings present sufficient to require home care / nursing assistance may be required / medications including steroids/anti-seizure agents may be required) (Cox, James D., et al "Toxicity criteria of the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer (EORTC)." International Journal of Radiation Oncology• Biology• Physics 31.5 (1995): 1341-1346).
Neurologically symptomatic patients must not require immediate surgical or radiation therapy for their symptoms, as decided by an investigator.
Have an Eastern Cooperative Oncology Group (ECOG) performance status ≤2.
Have adequate organ function, as determined by
For females of childbearing potential, have a negative pregnancy test documented prior to initiating brigatinib.
For female and male patients who are fertile, agree to use 2 effective methods of contraception with their sexual partners from the time of signing the informed consent through 4 months after the last dose of study drug, or agree to completely abstain from heterosexual intercourse. Brigatinib may decrease effectiveness of hormonal contraceptives, therefore, women are recommended to use non-hormonal methods of contraception. Highly effective non-hormonal birth control for women of child bearing potential with male partners includes:
Male patients, even if surgically sterilized (i.e., status post-vasectomy) must agree to 1 of the following:
Exclusion Criteria:
Patients who have received prior brigatinib therapy or other CNS-penetrant ALK TKIs, including alectinib, lorlatinib, or ceritinib.
RTOG/EORTC Acute CNS symptoms, grade 3 and 4 (Grade 3: Neurological findings requiring hospitalization for initial management; Grade 4: Serious neurological impairment that includes paralysis, coma, or seizures > 3 per week despite medication / hospitalization required).
Currently pregnant, planning a pregnancy during the study period, or breastfeeding.
Have clinically significant, uncontrolled cardiovascular disease per investigator, specifically including, but not restricted to:
Have uncontrolled hypertension per the investigator. Patients with persistent hypertension of systolic ≥140 or diastolic ≥90 mm Hg should be under treatment on study entry to control blood pressure.
Have a history or the presence at baseline of pulmonary interstitial disease, drug-related pneumonitis, or radiation pneumonitis.
Have an ongoing or active infection, including, but not limited to, the requirement for intravenous (IV) antibiotics.
Have a known history of human immunodeficiency virus (HIV) infection. Testing is not required in the absence of history.
Have a known or suspected hypersensitivity to brigatinib or its excipients.
Additional systemic therapies for the treatment of lung cancer may not be taken concomitantly with brigatinib (eg, TKIs, immunotherapy, chemotherapy). No washout period is required for prior therapy.
Have malabsorption syndrome or other GI illness that could affect oral absorption of brigatinib.
Have any condition or illness that, in the opinion of the investigator, would compromise patient safety or interfere with the evaluation of brigatinib.
Received systemic treatment with strong cytochrome p-450 (cyp)3a inhibitors, strong cyp3a inducers, or moderate cyp3a inducers within 14 days before enrollment.
Had major surgery within 30 days of the first dose of brigatinib. Minor surgical procedures such as catheter placement or minimally invasive biopsies are allowed.
Have been diagnosed with another primary malignancy other than NSCLC, except for adequately treated nonmelanoma skin cancer or cervical cancer in situ; definitively treated nonmetastatic prostate cancer; or patients with another primary malignancy who are definitively relapse-free with at least 3 years elapsed since the diagnosis of the other primary malignancy.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Chad Rusthoven, MD | University of Colorado, Denver | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| City of Hope | Duarte | California | 91010 | United States | ||
| University of Colorado Hospital |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Patients With ALK+ NSCLC and Brain Metastases | Including patients with brain metastases from ALK (anaplastic lymphoma kinase) positive NSCLC (non-small cell lung cancer), who are either neurologically asymptomatic or who have only mild neurologic symptoms (RTOG [Radiation therapy Oncology Group] acute neurologic morbidity score 0-2) from their brain metastases, who are TKI (tyrosine kinase inhibitor) naïve or who have had prior exposure to crizotinib, but who are naïve to brigatinib and other ALK TKIs including alectinib, lorlatinib, and ceritinib. Brigatinib: At day 1, all patients will be started on brigatinib 90 mg daily for 7 days, before escalating to 180 mg daily thereafter as tolerated. |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Patients With ALK+ NSCLC and Brain Metastases | Including patients with brain metastases from ALK (anaplastic lymphoma kinase) positive NSCLC (non-small cell lung cancer), who are either neurologically asymptomatic or who have only mild neurologic symptoms (RTOG [Radiation therapy Oncology Group] acute neurologic morbidity score 0-2) from their brain metastases, who are TKI (tyrosine kinase inhibitor) naïve or who have had prior exposure to crizotinib, but who are naïve to brigatinib and other ALK TKIs including alectinib, lorlatinib, and ceritinib. Brigatinib: At day 1, all patients will be started on brigatinib 90 mg daily for 7 days, before escalating to 180 mg daily thereafter as tolerated. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Number of Participants Who Meet Disease Control Rate (DCR) Criteria of Brain Metastases at 3 Months | DCR is defined as complete response (CR), partial response (PR), or stable disease (SD) as defined by the RANO-BM (Response Assessment in Neuro-Oncology Criteria - Brain Metastases) criteria. | Posted | Count of Participants | Participants | 13-week MRI ±7 days |
|
13 weeks
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Patients With ALK+ NSCLC and Brain Metastases | Including patients with brain metastases from ALK (anaplastic lymphoma kinase) positive NSCLC (non-small cell lung cancer), who are either neurologically asymptomatic or who have only mild neurologic symptoms (RTOG [Radiation therapy Oncology Group] acute neurologic morbidity score 0-2) from their brain metastases, who are TKI (tyrosine kinase inhibitor) naïve or who have had prior exposure to crizotinib, but who are naïve to brigatinib and other ALK TKIs including alectinib, lorlatinib, and ceritinib. Brigatinib: At day 1, all patients will be started on brigatinib 90 mg daily for 7 days, before escalating to 180 mg daily thereafter as tolerated. |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Non-Cardiac Chest Pain | Musculoskeletal and connective tissue disorders | CTCAE (4.0) | Non-systematic Assessment |
1 subject enrolled then study terminated due to low accrual. No further analyses completed.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dr. Chad Rusthoven | University of Colorado Hospital | 720-516-0150 | chad.rusthoven@cuanschutz.edu |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Dec 29, 2021 | Aug 15, 2022 | Prot_SAP_000.pdf |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001932 | Brain Neoplasms |
| D008175 | Lung Neoplasms |
| ID | Term |
|---|---|
| D016543 | Central Nervous System Neoplasms |
| D009423 | Nervous System Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
Not provided
Not provided
| ID | Term |
|---|---|
| C000598580 | brigatinib |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Time until any local PD (i.e., in brain lesions identified at the time of enrollment) by RANO-BM criteria and rates at follow up intervals
| up to 24 months |
| Time Until Progression With Brigatinib Alone (Part 3) | Time until any distant brain PD (i.e., new brain lesions that were not present at the time of enrollment) by RANO-BM criteria and rates at follow up intervals | up to 24 months |
| Time Until Progression With Brigatinib Alone (Part 4) | Time until progression at any site using RANO-BM for intracranial disease and RECIST for extracranial disease and rates at follow up intervals | up to 24 months |
| Overall Survival With a Strategy of Brigatinib Alone | Time until death from any cause and rates at follow up intervals | up to 24 months |
| Time Until Brain Metastases-Specific Mortality | Defined as time to intracranial progression as a component of cause of death and rates at follow up intervals | up to 24 months |
| Brain Metastases Objective Response Rates (ORR) With Brigatinib Alone | Cumulative rate of best responses individually for complete response (CR), partial response (PR), stable disease (SD), by RANO-BM criteria | up to 24 months |
| Time Until the Administration of WBRT With Brigatinib Alone | Time until the administration of whole brain-radiotherapy (WBRT) and rates at follow up intervals | up to 24 months |
| Longitudinal Changes in Quality of Life With Brigatinib Alone | Quality of life will be assessed using standardized QOL metrics (EORTC QLQ C30/BN 20) | up to 24 months |
| Characterization of Corticosteroid Administration Before and After Brigatinib Initiation | Quantification of the agent and dosage of corticosteroids at each study assessment | up to 24 months |
| Aurora |
| Colorado |
| 80045 |
| United States |
| Mayo Clinic | Rochester | Minnesota | 55905 | United States |
| Participants |
|
| Age, Continuous | Mean | Full Range | years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
|
|
| Secondary | Time Until Progression With Brigatinib Alone (Part 1) | Time until any CNS progressive disease (PD) by RANO-BM criteria and rates at follow up intervals | Trial was terminated early due to low accrual. No data were collected for this outcome measure because the patient was only followed for 13 weeks, and progression did not occur during this time. | Posted | up to 24 months |
|
|
| Secondary | Time Until Progression With Brigatinib Alone (Part 2) | Time until any local PD (i.e., in brain lesions identified at the time of enrollment) by RANO-BM criteria and rates at follow up intervals | Trial was terminated early due to low accrual. No data were collected for this outcome measure because the patient was only followed for 13 weeks, and progression did not occur during this time. | Posted | up to 24 months |
|
|
| Secondary | Time Until Progression With Brigatinib Alone (Part 3) | Time until any distant brain PD (i.e., new brain lesions that were not present at the time of enrollment) by RANO-BM criteria and rates at follow up intervals | Trial was terminated early due to low accrual. No data were collected for this outcome measure because the patient was only followed for 13 weeks, and progression did not occur during this time. | Posted | up to 24 months |
|
|
| Secondary | Time Until Progression With Brigatinib Alone (Part 4) | Time until progression at any site using RANO-BM for intracranial disease and RECIST for extracranial disease and rates at follow up intervals | Trial was terminated early due to low accrual. No data were collected for this outcome measure because the patient was only followed for 13 weeks, and progression did not occur during this time. | Posted | up to 24 months |
|
|
| Secondary | Overall Survival With a Strategy of Brigatinib Alone | Time until death from any cause and rates at follow up intervals | Trial was terminated early due to low accrual. No data were collected for this outcome measure because the patient was only followed for 13 weeks and did not die. | Posted | up to 24 months |
|
|
| Secondary | Time Until Brain Metastases-Specific Mortality | Defined as time to intracranial progression as a component of cause of death and rates at follow up intervals | Trial was terminated early due to low accrual. No data were collected for this outcome measure because the patient was only followed for 13 weeks, and neither progression nor death occurred during this time. | Posted | up to 24 months |
|
|
| Secondary | Brain Metastases Objective Response Rates (ORR) With Brigatinib Alone | Cumulative rate of best responses individually for complete response (CR), partial response (PR), stable disease (SD), by RANO-BM criteria | Trial was terminated early due to low accrual. No data were collected for this outcome measure because the patient was only followed for 13 weeks. | Posted | up to 24 months |
|
|
| Secondary | Time Until the Administration of WBRT With Brigatinib Alone | Time until the administration of whole brain-radiotherapy (WBRT) and rates at follow up intervals | Trial was terminated early due to low accrual. No data were collected for this outcome measure because the patient was only followed for 13 weeks and did not receive WBRT before trial termination. | Posted | up to 24 months |
|
|
| Secondary | Longitudinal Changes in Quality of Life With Brigatinib Alone | Quality of life will be assessed using standardized QOL metrics (EORTC QLQ C30/BN 20) | Trial was terminated early due to low accrual. No scores were computed for this outcome measure because the patient was only followed for 13 weeks out of the intended 104 weeks and longitudinal changes could not be analyzed. | Posted | up to 24 months |
|
|
| Other Pre-specified | Analysis of Blood at Baseline and at Progression to Correlate With Clinical Outcomes | Evaluation of cfDNA at baseline and progression to correlate with clinical outcomes, including incidence of disease recurrence per RANO-BM and RECIST 1.1, survival status by percentage of patients alive at 2 years, and patient rating of quality of life per EORTC QLQ-BN20 and EORTC QLQ-C30 questionnaires. | Trial was terminated early due to low accrual. No data were collected for this outcome measure because the patient was only followed for 13 weeks, and no progression occurred during this time. | Posted | up to 24 months |
|
|
| Other Pre-specified | Characterization of Corticosteroid Administration Before and After Brigatinib Initiation | Quantification of the agent and dosage of corticosteroids at each study assessment | Trial was terminated early due to low accrual. No data were collected for this outcome measure because the patient was only followed for 13 weeks and had not been administered any corticosteroids during this time. | Posted | up to 24 months |
|
|
| 0 |
| 1 |
| 0 |
| 1 |
| 1 |
| 1 |
| Somnolence | General disorders | CTCAE (4.0) | Non-systematic Assessment |
|
| Sinus Tachycardia | Cardiac disorders | CTCAE (4.0) | Non-systematic Assessment |
|
| Constipation | Gastrointestinal disorders | CTCAE (4.0) | Non-systematic Assessment |
|
| Hyponatremia | Blood and lymphatic system disorders | CTCAE (4.0) | Non-systematic Assessment |
|
| CPK increased | Blood and lymphatic system disorders | CTCAE (4.0) | Non-systematic Assessment |
|
| Diarrhea | Gastrointestinal disorders | CTCAE (4.0) | Non-systematic Assessment |
|
| Vocal Cord Paralysis | Respiratory, thoracic and mediastinal disorders | CTCAE (4.0) | Non-systematic Assessment |
|
| xerosis | Skin and subcutaneous tissue disorders | CTCAE (4.0) | Non-systematic Assessment |
|
| Nausea | Gastrointestinal disorders | CTCAE (4.0) | Non-systematic Assessment |
|
Not provided
Not provided
Not provided
| D001927 |
| Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D012142 | Respiratory Tract Neoplasms |
| D013899 | Thoracic Neoplasms |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |